Boardroom Alpha
Boardroom Alpha
STLN · Additional Proxy Materials (DEFA14A) · Filed April 30, 2026

Starling Oncology Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 30, 2026
Ticker
STLN
Accession
0001193125-26-197376
Boardroom Alpha · Filing insights

The Oncology Institute, Inc. board recommends votes FOR Proposals 1-3 and selects a 1-year frequency for Proposal 4.

About Starling Oncology Inc
Market cap
$664M
1Y TSR
+94.3%
3Y TSR
+65.2%
Board grade
C
Sector
Healthcare
CEO
Daniel Virnich
Last annual meeting: Jun 17, 2026 · View full Starling Oncology Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

☐

Preliminary Proxy Statement

 

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐

Definitive Proxy Statement

 

☒

Definitive Additional Materials

 

☐

Soliciting Material under §240.14a-12

The Oncology Institute, Inc.

(Name of Registrant as Specified In Its Charter)

NOT APPLICABLE

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

☒

No fee required.

 

☐

Fee paid previously with preliminary materials.

 

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 
 


LOGO

PROXY TABULATOR: P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders The Oncology Institute, Inc. Meeting to Be Held on June 17, 2026 for Stockholders of Record as of April 24, 2026 Annual Meeting of Stockholders To order paper materials, use one of the ednesday, June 17, 2026 11:00 AM, Pacific Time Annual Meeting to be held live via the internet—please visit .proxydocs.com/TOI for more follo ing methods. details. You must register to attend the Annual Meeting online and/or participate at .proxydocs.com/TOI Internet: For a convenient ay to vie proxy materials, VOTE, and obtain .investorelections.com/TOI directions to attend the meeting go to .proxydocs.com/TOI To vote your proxy hile visiting this site, you ill need the 12 digit control number in the box belo . Call: 1-866-648-8133 This communication presents only an overvie of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. e encourage you to access and revie all of the important information contained in the proxy materials before voting. Email: paper@investorelections.com Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the * If requesting material by e-mail, please send a blank e-mail ith the Internet. 12 digit control number (located belo ) in the subject line. No other requests, instructions OR other inquiries should be included ith your If you ant to receive a paper or e-mail copy of the proxy material, you must request one. e-mail requesting material. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 5, 2026. Your control number Have the 12 digit control number located in the box above available hen you access the ebsite and follo the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


LOGO

The Oncology Institute, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2 AND 3 1 YEAR ON PROPOSAL 4 PROPOSAL 1. Election of eight directors. 1.01 Brad Hively 1.02 Karen Johnson 1.03 Mohit Kaushal 1.04 Anne McGeorge 1.05 Mark Pacala 1.06 Mark Stolper 1.07 Kimberly Tzoumakas 1.08 Daniel Virnich 2. Ratification of the appointment of BDO as the independent registered public accounting firm of the Company for 2026. 3. Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. 4. Approval, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Starling Oncology Inc (STLN)

Reference

Frequently asked questions

When did Starling Oncology Inc file this DEFA14A?
Starling Oncology Inc (STLN) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 30, 2026. The accession number assigned by EDGAR is 0001193125-26-197376.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
The Oncology Institute, Inc. board recommends votes FOR Proposals 1-3 and selects a 1-year frequency for Proposal 4. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Starling Oncology Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Starling Oncology Inc has filed under CIK 1799191, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer